Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

BIIB037

Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.

OTHER

Placebo

Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.

Trial Locations (3)

32806

Compass Research, LLC, Orlando

33445

Brain Matters Research, Delray Beach

44122

Insight Clinical Trials, LLC, Beachwood

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01397539 - Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease | Biotech Hunter | Biotech Hunter